

A. JANSSENS, MD, PHD

**DEAR COLLEAGUES,**

Welcome to the first regular issue of the BJH 2025.

Before going through the content of this issue, the editorial board of the BJH wants to congratulate **Prof. Ann De Becker as 13th President of the BHS** for the upcoming three years. In her interview we will learn how she, together with the BHS board, wants to meet the BHS mission “Best care for every patient with a haematological problem in Belgium”.

The manuscript “**Prime-time for long non-coding RNA (lncRNA) signatures in acute myeloid leukaemia**” by Z. Ren *et al.* (Department of Paediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent) has been selected for **REVIEW HEMATOLOGY**. The authors describe the strengths and shortcomings of these signatures to personalise treatment strategies.

“**Luspatercept in lower-risk myelodysplastic syndromes: Belgian real-life data into perspective**” by B. Heyrman *et al.* (Department of Haematology, ZAS, Antwerp) has been chosen for **PHARMACOTHERAPY**. The authors confirm the efficacy but also the lack of quality-of-life data to select patients suitable for this treatment better.

HEMATOCASE presents “**Severe ADAMTS13 deficit and thrombocytopenia in a case of newly diagnosed systemic lupus erythematosus with antiphospholipid syndrome**” by L. Dassy *et al.* (Department of Haematology, CHU Liège, Liège). The rapid initiation of treatment probably prevented the occurrence of thrombotic microangiopathy and provided a favourable serological and clinical evolution of the lupus with APL syndrome of this patient.

“**The complementary value of human and canine mast cell neoplasia**” from S. De Vos *et al.* (Faculty of Veterinary Medicine, Ghent University, Merelbeke) is the subject of **HEMATOTHESIS**. Since mast cell tumours are common in dogs, they could provide a translational model studying this tumour type in humans.

The issue concludes with the **oral and poster presentations** selected from the annual meeting of the **Belgian Society on Thrombosis and Haemostasis (BSTH)**, which took place on 27-28 November 2024, in Mechelen.

Enjoy reading,

Ann Janssens, MD, PhD
Editor-in-Chief